New hope for brain metastases in HER2-low breast cancer?
NCT ID NCT07150208
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase II trial tests whether adding bevacizumab to trastuzumab deruxtecan (T-DXd) works better than T-DXd alone for people with HER2-low breast cancer that has spread to the brain and cannot be removed by surgery. The study will enroll 140 participants and measure how long the cancer stays under control. It is an early-stage trial, so results will help guide future research rather than provide a proven treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab deruxtecan (T-DXd) and bevacizumab
- What this could lead to
- If successful, this could provide a new treatment option for people with HER2-low breast cancer that has spread to the brain, potentially slowing disease progression.
- What could go wrong
- This is a Phase II trial with only 140 participants, so results are preliminary. The combination may not improve outcomes over T-DXd alone, and bevacizumab carries risks like high blood pressure and bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER WITH BRAIN METASTASIS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.